Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2019 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, May 30, 2019
Slide 1: Cover letter to stock exchanges
<8> ALKEM ALKEM LABORATORIES LTD. Regd. Office: "ALKEM HOUSE", Senapati Bapat Marg, Lower Parei, MUMBAI 400 013. Phone : 3982 9999, Fax : 022-2495 2955 Email : contact@alkem.com Website : www.alkemlabs.com GIN no.:- L00305MH1973PLC174201 30th May, 2019 The Corporate Relationship Department National
Slide 2: Press Release: Alkem reports Q4FY19 and FY19 Results
<8> ALKEM ALKEM LABORATORIES LTD. Regd. Office: "ALKEM HOUSE", Senapati Bapat Marg, Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Email : contact@alkem.com Website : www.alkemlabs.com CIN no.:- L00305MH1973PLC174201 Press Release Alkem reports Q4FV19 and FY19 Results Mumbai,
Slide 3: Operational Highlights
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg, Lower Parel , MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Email : contact@alkem .com Website : www.alkemlabs.com CIN no.:- L00305MH1973PLC174201 Operational Highlight s India Business In Q4FY19, the Com
Slide 4: Other International Markets and R&D Investments
~ ALKEM ALKEM LABORATORIES LTD. Regd. Office: "ALKEM HOUSE", Senapati Bapat Marg, Lower Pare!, MUMBAI 400 013. Phone: 3982 9999, Fax: 022 - 2495 2955 Email : contact@alkem.com Website : www.alkemlabs .com CIN no.:- L00305MH1973PLC174201 • Other International Markets sales for the quarter was Rs.1,27
Slide 5: Q4FY19 and FY19 Conference Call
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office: "ALKEM HOUSE", Senapati Bapat Marg, Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022 - 2495 2955 Email : contact@alkem.com Website : www.alkemlabs.com GIN no.:- L00305MH1973PLC174201 Q4FY19 and FY19 Conference Call at 5:30pm 1ST, May 30, 2019
Slide 6: Investor Presentation Q4FY19 – May 30, 2019
Investor Presentation Q4FY19 – May 30, 2019
Slide 7: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 8: Key Highlights of Q4FY19 and FY19
Key Highlights of Q4FY19 and FY19 • India Business: Company’s India sales registered a growth of 26.8% YoY in Q4FY19 and 8.6% in FY19 • Company’s secondary sales in FY19 grew by 14.3% YoY - higher than IPM growth of 10.5% YoY (Source: IQVIA MAT March 2019) • International Business: Company’s Interna
Slide 9: Key Financial Highlights – Q4FY19 (Consolidated)
Key Financial Highlights – Q4FY19 (Consolidated) All figures in Rs mn Revenue from Operations India sales 12,176 18,542 9,602 14,920 Q4FY18 Q4FY19 International sales 6,097 5,130 Q4FY18 Q4FY19 Q4FY18 Q4FY19
Slide 10: Key Financial Highlights – Q4FY19 (Consolidated)
Key Financial Highlights – Q4FY19 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 10,786 2,350 9,126 1,030 61.2% 58.2% 6.9% 12.7% Q4FY18 Q4FY19 Q4FY18 Q4FY19 PBT (before Minority Interest) PAT (after Minority Interest) 1,674 1,988 809 671 Q4FY18 Q4FY19 Q4FY
Slide 11: Key Financial Highlights – FY19 (Consolidated)
Key Financial Highlights – FY19 (Consolidated) Particulars (Rs mn) FY19 FY18 YoY growth Revenue from Operations 73,572 64,012 14.9% Gross Profit 44,122 40,184 9.8% Gross Profit margin 60.0% 62.8% EBITDA 11,148 10,089 10.5% EBITDA margin 15.2% 15.8% PBT 9,547 9,260 3.1% PBT margin 13.0% 14.5% PAT (Af
Slide 12: India Business
India Business India Business: Q4FY19 Sales of Rs.12,176 million (26.8% YoY growth) • India sales contributed 66.6% to total sales in Q4FY19 • Adjusting for the impact of change in distribution policy, the YoY growth in domestic business in Q4FY19 was in early teens • In Q4FY19, Company’s secondary
Slide 13: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across most of the major therapeutic areas in FY19 Established therapeutic Market rank 1 3 3 4 areas of Alkem 17.9% 15.4% 13.7% 12.0% 7.9% 7.7% 9.0% 6.6% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alke
Slide 14: US Business
US Business US Business: Q4FY19 Sales of Rs.4,822 million (18.5% growth YoY) • US sales contributed 26.4% to total sales in Q4FY19 • In Q4FY19, the Company filed 9 ANDAs with the US FDA and received 11 approvals (including 2 tentative approval) • In FY19, the Company filed 23 ANDAs with the US FDA a
Slide 15: Update on the US FDA inspection
Update on the US FDA inspection Facility Scope Last inspection Status post last inspection Baddi (India) Formulation May 2019 Received Form 483 with 4 observations St. Louis (US) Formulation February – March 2019 Received Form 483 with 8 observations. Plant classified as OAI* Daman (India) Formulati
Slide 16: Other International Business
Other International Business Other International Business: Q4FY19 Sales of Rs.1,275 million (20.3% YoY growth) • Other International Market sales contributed 7.0% to total sales in Q4FY19 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Chile and Phil
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on March 31, 2019 Non-Institution, 26.20% Promoter & Institution, Promoter Group, 7.78% 66.02% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodie
Slide 18: Thank You
Thank You DP ar @.